San Francisco, 26 December 2018: The Report Blood Screening Market Size, Share & Trends Analysis Report By Product
(Reagent, Instrument), By Technology (NAT, ELISA, CLIA & EIA, NGS, Western
Blotting), By Region, And Segment Forecasts, 2018 - 2024
The global blood screening market is expected to reach a value of USD 3.9 billion by 2024, based on a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.
Thorough screening is necessary for all donated blood to
ensure that recipients receive the safest products. As of 2015, such testing
consists of screening for red cell antibodies, and the infectious diseases
agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human
T-Lymphotropic Virus (HTLV) T. Cruzi, and T.
pallidum (syphilis). The result of all these assays must be
negative for blood donation.
Technological developments increase the
sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA
approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen
donated blood. Furthermore, the U.S. FDA approved next-generation sequencing
(NGS) technology in 2013. The technology is cheaper and faster than previous
DNA analysis methods.
Access Research Report of Blood Screening Market @ www.grandviewresearch.com/industry-analysis/blood-screening-market
Further
Key Findings from the Study Suggest:
· Nucleic acid amplification test or nucleic
acid test (NAT) is expected to be the fastest growing segment during the
forecast period. It comprises transcription mediated amplification (TMA) tests
and polymerase chain reaction. Increasing demand of NAT over ELISA test due to
high sensitivity and specificity for viral nucleic acid is contributing to the
fastest growth during the forecast period. The American Red Cross implemented
automated triplex NAT for HCV, HIV, and HBV in 2009. This would further boost
the industry.
· In 2015, reagent dominated the product
segment. Introduction of new assays for the detection of various diseases is
expected to enable the segment to gain the maximum share in the coming years.
For instance, in January 2015 the FDA approved Roche’s blood screening assay
COBAS TaqScreen MPX Test for the detection and identification of HCV, HIV, and
HBV.
· In 2015, regionally North America dominated
with a revenue share of more than 40%. Government initiatives, presence of
major players, and more patient affordability are the major factors that
contributed toward its dominance. The U.S. FDA strengthens regulations that
protect patients from unsuitable products.
· Recently, the FDA published a guidance
document proposing regulations for laboratory developed tests. In addition, In
February 2015, the U.S. FDA conducted a workshop to discuss the oversight of
NGS. All these factors increase awareness, which would further increase the
growth of the industry.
· In August 2016, the FDA recommended the
testing of all the donated blood in the U.S. and its territories for Zika virus
in order to prevent transmission of this virus through the blood supply.
· Asia Pacific is expected to be the fastest
growing region due to increasing investment of industry players, government
initiatives, and rising awareness about transmission of diseases during its
transfusion.
· The Red Cross in Japan entered into a
contract with Grifols for nucleic acid testing (NAT) for a donation camp in
Japan in 2014. This agreement is anticipated to propel the NAT during the
forecast period. However, low donation as compared to requirement and high cost
of kits and instruments are likely to restrain the growth in low-income
countries during the forecast period.
· In June 2015, India launched a National
Blood Donor Vigilance Programme (NBDVP) to undertake donor vigilance activity.
Such initiatives from emerging countries improve the donor safety and
satisfaction and thereby drives the market in coming years.
· Some of the players operating in the
industry are Abbott Laboratories; Danaher Corporation (Beckman Coulter); Becton
Dickinson and Company; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.;
Grifols; Ortho-Clinical Diagnostics, Inc.; Siemens AG; and Thermo Fisher
Scientific. Partnerships and acquisitions play an important role in capturing
the market. Competition between the industry players is rigorous due to the
presence of advanced instruments and assays.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the blood
screening market by product, technology, and region:
Blood Screening Technology Outlook
(Market Revenue in USD Million, 2013 - 2024)
·
Nucleic Acid Amplification Test (NAT)
·
ELISA
·
Chemiluminescence Immunoassay (CLIA) and
Enzyme Immunoassay (EIA)
·
Next-Generation Sequencing (NGS)
·
Western Blotting
Blood Screening Product Outlook
(Market Revenue in USD Million, 2013 - 2024)
·
Reagent
·
Instrument
Blood Screening Regional Outlook
(Market Revenue in USD Million, 2013 - 2024)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
Middle East and Africa
Access Press Release of
Blood Screening Market@ www.grandviewresearch.com/press-release/global-blood-screening-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment